171 related articles for article (PubMed ID: 38302118)
1. Genetic Association of Lipid-Lowering Drugs with Aortic Aneurysms: A Mendelian Randomization Study.
Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
Eur J Prev Cardiol; 2024 Feb; ():. PubMed ID: 38302118
[TBL] [Abstract][Full Text] [Related]
2. Analyzing the causal relationship between lipid-lowering drug target genes and epilepsy: a Mendelian randomization study.
Huang S; Liu Y; Zhang Y; Wang Y; Gao Y; Li R; Yu L; Hu X; Fang Q
Front Neurol; 2024; 15():1331537. PubMed ID: 38523609
[TBL] [Abstract][Full Text] [Related]
3. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
[TBL] [Abstract][Full Text] [Related]
4. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
Miao L; Miao T; Zhang Y; Hao J
BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
[TBL] [Abstract][Full Text] [Related]
5. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
6. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
7. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
8. Association between Lipid Levels and Risk for Different Types of Aneurysms: A Mendelian Randomization Study.
Chen Y; Huang M; Xuan Y; Li K; Xu X; Wang L; Sun Y; Xiao L; Xu P; Kong W; Wang DW
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834523
[TBL] [Abstract][Full Text] [Related]
9. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
Bi Y; Zhu Y; Tang S; Huang Y
J Headache Pain; 2023 Aug; 24(1):112. PubMed ID: 37596566
[TBL] [Abstract][Full Text] [Related]
10. Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study.
Xu Y; Li Y
World Allergy Organ J; 2024 Apr; 17(4):100899. PubMed ID: 38623319
[TBL] [Abstract][Full Text] [Related]
11. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
12. Association of lipid lowering drugs and the risk of systemic lupus erythematosus: a drug target Mendelian randomization.
Wu T; Ye L; Wang S; Huang J; Zhang J
Front Pharmacol; 2023; 14():1258018. PubMed ID: 37964871
[No Abstract] [Full Text] [Related]
13. Estimating the effect of lipid-lowering agents on novel subtypes of adult-onset diabetes.
Ye J; Guo K; Li J; Li X; Zhou Z; Yang L
Diabetes Metab Res Rev; 2024 May; 40(4):e3793. PubMed ID: 38661109
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
15. Association between Lipid-Lowering Drugs and Traumatic Subdural Hemorrhage: A Mendelian Randomization Study.
Chen K; Li H; Chen Y; Huang H; Wei L
J Integr Neurosci; 2024 Apr; 23(4):76. PubMed ID: 38682216
[TBL] [Abstract][Full Text] [Related]
16. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
17. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
18. Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study.
Dong H; Chen R; Xu F; Cheng F
Clin Epidemiol; 2024; 16():131-141. PubMed ID: 38410417
[TBL] [Abstract][Full Text] [Related]
19. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
20. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
